Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its cystic fibrosis focus into endocrine disease treatments. The deal could add up to $5 billion in annual revenue through approved drug Palsonify and pipeline candidate Atumelnant. While Vertex's stock initially fell post-announcement, the author suggests it could be a solid long-term buy given management's track record and enhanced growth prospects, despite the 29x trailing earnings valuation.

07/13/2026, 2:27 PM • The Motley Fool

Why This Pharmaceutical Stock Jumped Close to 100% This Week

Crinetics Pharmaceuticals stock surged 98% this week following Vertex Pharmaceuticals' announcement of a $10 billion acquisition deal. Crinetics, which recently had its first FDA-approved drug (Palsonify) for acromegaly treatment, is now trading just below the $85 per share acquisition price. The deal allows Vertex to diversify beyond its cystic fibrosis focus into rare diseases, with combined assets projected to generate $5 billion in annual revenue.

07/10/2026, 3:02 PM • The Motley Fool

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its dominant cystic fibrosis portfolio into rare endocrine disorders. The deal provides access to Palsonify for acromegaly and a pipeline asset for congenital adrenal hyperplasia, potentially adding $5 billion in peak annual revenue. While the price is fair and strategically sound, results aren't expected until 2029, making it a long-term growth play for the biotech company.

07/10/2026, 4:05 AM • The Motley Fool

Halper Sadeh LLC is Investigating Whether CRNX, ESI, INVE, SLP are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholders' interests.

07/08/2026, 2:35 PM • GlobeNewswire

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, representing a 102% premium to the pre-announcement price. The deal aims to expand Vertex beyond its core cystic fibrosis business into rare disease therapeutics, with immediate revenue from FDA-approved PALSONIFY for acromegaly and Phase 3 candidate Atumelant for congenital adrenal hyperplasia. While analysts view the strategic fit positively, the deal presents integration risks and questions about pipeline depth.

07/08/2026, 10:22 AM • Investing

Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.

Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion ($85 per share), representing a 102% premium. The deal gives Vertex access to Palsonify, an FDA-approved acromegaly treatment, and atumelnant, a late-stage Phase 3 drug candidate for congenital adrenal hyperplasia with potential multi-billion dollar sales potential. The analyst views the acquisition as worthwhile despite the high price tag.

07/08/2026, 3:28 AM • The Motley Fool

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Crinetics Pharmaceuticals announced positive Phase 2 trial results for atumelnant, an oral ACTH receptor antagonist for treating congenital adrenal hyperplasia (CAH). The drug demonstrated sustained androgen reductions while enabling patients to lower glucocorticoid supplementation to physiologically normal levels. Additional Phase 1b/2a data in ACTH-dependent Cushing's syndrome showed rapid cortisol reduction. The company is advancing atumelnant into late-phase clinical development with Phase 3 trials already underway.

06/14/2026, 4:30 PM • GlobeNewswire

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Crinetics Pharmaceuticals announced long-term clinical data from PATHFNDR-1 and PATHFNDR-2 trials showing that PALSONIFY (paltusotine) maintains effective acromegaly control for up to two years with stable IGF-1 levels, symptom control, and pituitary tumor stabilization. Additional data demonstrated improved biochemical control when PALSONIFY is combined with cabergoline. The drug was well-tolerated with no new safety signals identified.

06/14/2026, 2:45 PM • GlobeNewswire

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Crinetics Pharmaceuticals announced it will present six abstracts at the Endocrine Society's Annual Meeting (ENDO 2026) in June, including oral presentations featuring long-term efficacy and safety data for PALSONIFY (paltusotine) in acromegaly and Phase 2 results for investigational ACTH receptor antagonist atumelnant in congenital adrenal hyperplasia and Cushing's syndrome. The company also reported Q1 2026 net product revenue of $10.3 million for PALSONIFY with 232 enrollment forms.

06/02/2026, 4:55 AM • GlobeNewswire

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

Neutrolis Inc., a clinical-stage biotech company focused on treating autoimmune and inflammatory diseases, announced the appointment of Caren Deardorf as Chief Business & Strategy Officer. Deardorf brings over 30 years of executive leadership experience in commercialization and product launches, previously serving as Chief Commercial & Strategy Officer at Editas Medicine, Magenta Therapeutics, and Ohana Biosciences. She will lead business development and commercial strategy as Neutrolis advances its NTR-1011 candidate following positive Phase 1a results.

04/15/2026, 2:00 PM • GlobeNewswire

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Crinetics Pharmaceuticals announced it will report Q4 and full year 2025 financial results on February 26, 2026, with a management conference call at 4:30 p.m. ET. The company also recently initiated a Phase 2/3 pediatric trial for atumelnant in congenital adrenal hyperplasia and announced January 2026 inducement grants.

01/26/2026, 5:00 PM • GlobeNewswire

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals announced a conference call scheduled for January 5, 2026 to provide a commercialization update on PALSONIFY (paltusotine) and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. The company's lead product PALSONIFY is the first once-daily oral treatment approved by the FDA for acromegaly, while atumelnant is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.

01/04/2026, 4:00 PM • GlobeNewswire

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Crinetics Pharmaceuticals initiated a Phase 1/2 clinical trial for CRN09682, an investigational nonpeptide drug conjugate targeting somatostatin receptor type 2-positive neuroendocrine tumors, marking a significant milestone in developing a potentially more precise targeted therapy.

12/03/2025, 8:00 AM • GlobeNewswire

Why Crinetics Pharmaceuticals Stock Was Sliding on Friday

Crinetics Pharmaceuticals reported Q3 earnings with lower-than-expected revenue and increased net losses, despite receiving FDA approval for its acromegaly treatment Palsonify and securing a licensing agreement with Sanwa Kagaku Kenkyusho.

11/07/2025, 4:16 PM • The Motley Fool

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals granted stock options and restricted stock units to 20 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan, with options and RSUs vesting over four years.

10/10/2025, 4:41 PM • GlobeNewswire